explore -WSS

explore

author：focus 2025-10-02 10:48:41 - browse：2

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： The FDA must approve intranasal treatments for anaphylaxis

entertainment

WSS

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Goldman Sachs launches $650M fund for life science investments

Travel bans should be based on evidence, not politics or fear

Sage's campaign to raise awareness of postpartum depression hits a nerve

focus

explore

focus

Anesthesiologist group: stop taking Ozempic before surgery

Sage's campaign to raise awareness of postpartum depression hits a nerve

BioMarin wins approval for gene therapy to treat hemophilia A

Travel bans should be based on evidence, not politics or fear

Hepatitis C has a cure — but many Americans still lack access to it

Former Georgia lieutenant governor says he received grand jury subpoena

As demand for Covid shots wanes, Moderna seeks its next success

Choosing scientific sides in the fight against Alzheimer's

Apple is now the first public company to be valued at $3 trillion

The FDA must approve intranasal treatments for anaphylaxis

knowledge

New weight loss drugs work. But how can they best be used?

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Why psychiatrists like me stop taking insurance

UCB departs biotech trade group BIO

entertainment

entertainment

focus

focus